This trial is evaluating whether Sitravatinib will improve 2 primary outcomes and 4 secondary outcomes in patients with Kidney Neoplasms. Measurement will happen over the course of Up to 6 weeks.
This trial requires 42 total participants across 1 different treatment group
This trial involves a single treatment. Sitravatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Tumor treatment is highly individualized and tailored. Given the prevalence of kidney cancer, however, the information provided by the Mayo Clinic to help patients with this disease is both helpful and necessary." - Anonymous Online Contributor
"Nephromyelo-sarcoma may present with a small, non-symptomatic, red-blood cell mass in the renal and urinary tract, or as an asymptomatic haematuria. Haematuria in a young man should lead to prompt investigation for carcinoma." - Anonymous Online Contributor
"Even though no cause has been found for all types of RCC, there is a clear relationship between the occurrence of certain risk factors and the development of the disease in patients with renal failure." - Anonymous Online Contributor
"If carcinoma of the renal cortex, renal capsule and/or distal convoluted tubulla is successfully surgically removed, this can be an end-stage renal disease if not recurrent and well treated. If recurrence occurs, repeated surgeries can be necessary to improve the patient's condition. However, only a tiny percentage of patients who are successfully treated become disease-free." - Anonymous Online Contributor
"Carcinoma, renal cell is the most common type of renal cancer. It is the major cause of kidney failure-related death in developing countries, such as Pakistan. The most common forms of skin cancer are Basal cell carcinoma, Squamous cell carcinoma and Malignant Melanoma of the Non-Acquired type. The prevalence of this disease continues to increase across the world due to environmental factors, as a part of the non-communicable disease cluster associated with tobacco use." - Anonymous Online Contributor
"The incidence of renal cell carcinoma in the United States is increasing. The incidence of other types of renal cell carcinomas remain stable. As the incidence of renal cell carcinoma increases, physicians' attention to the diagnosis of renal cell carcinoma is important because renal cell carcinoma is relatively treatable." - Anonymous Online Contributor
"The rate of dose-limiting toxicities was low in this study. There was no evidence of renal function impairment at doses up to 100 mg bid." - Anonymous Online Contributor
"Stat3 plays a key role in cancer progression and survival. Sitravatinib acts as an inhibitor of vascular endothelial growth factor (VEGF) receptor (VEGFR)-2, which leads to suppression of angiogenesis and tumor vasculature growth, and consequent tumor shrinkage." - Anonymous Online Contributor
"The current research is using clinical trials as part of the treatment and management of carcinoma, renal cell. Some of the cancers patients may use trials that can be prescribed to improve their chances of keeping alive and well after cancer treatments. Some of the cancers that are being studied are kidney cancer, breast cancer, prostate cancer, colorectal cancer, and non-small-cell lung cancer. These cancer treatments can get better as the cancer clinical trial research goes on." - Anonymous Online Contributor
"Sitavatinib is a promising drug. We present data showing that sitavatinib inhibits the growth of a wide range of human solid and liquid tumors that exhibit a range of phenotypes. Sitavatinib deserves further development for a variety of indications." - Anonymous Online Contributor
"The overall survival of patients with metastatic renal cell carcinoma in the U.S. with metastatic disease can be improved by combining aggressive surgical intervention for cancer and aggressive chemotherapy that should focus on metastatic disease." - Anonymous Online Contributor
"This pilot study, involving six patients, is the first report describing the safety and antitumor activity of sitravatinib, in vitro and in vivo, in human malignant cells. The antitumor activity of sitravatinib in this pilot study suggests that its use might have a role in the treatment of patients with advanced RCC." - Anonymous Online Contributor